What are the International Normalized Ratio (INR) targets for common conditions and when is warfarin preferred over Direct Oral Anticoagulants (DOACs) like apixaban (apixaban), rivaroxaban (rivaroxaban), and dabigatran (dabigatran)?

INR Targets and When to Use Warfarin Over DOACs

Standard INR Targets for Common Conditions

For atrial fibrillation and most thromboembolic conditions requiring warfarin, the target INR is 2.0-3.0, aiming for a midpoint of 2.5 to maximize time in therapeutic range. 1

Specific INR Targets by Condition:

• Nonvalvular Atrial Fibrillation: INR 2.0-3.0 1
• Mechanical Heart Valves: INR 2.0-3.0 or 2.5-3.5 depending on valve type and location 1
• Left Ventricular Thrombus: INR 2.0-3.0 2
• End-Stage Renal Disease/Hemodialysis: INR 2.0-3.0 (warfarin preferred) 1

Critical INR Thresholds:

• Below 2.0: Significantly increased risk of thromboembolism and ischemic stroke 1
• Above 3.0: Increased incidence of major bleeding 1
• Above 3.5: Markedly elevated risk of intracranial hemorrhage 1

Time in Therapeutic Range (TTR) Requirements:

Warfarin therapy requires TTR ≥65-70% to be considered adequately controlled; if TTR falls below 65%, switch to DOACs or implement intensive interventions. 1

• Optimal TTR target: ≥70% 1, 2
• Action threshold: <65% requires intervention or DOAC switch 1

---

When Warfarin is REQUIRED Over DOACs (Absolute Indications)

Mechanical Heart Valves:

Warfarin is mandatory for all patients with mechanical heart valves—DOACs are absolutely contraindicated. 1, 2

• Dabigatran demonstrated inferior efficacy and increased bleeding in the RE-ALIGN trial 1
• Target INR 2.0-3.0 or 2.5-3.5 based on valve type and position 1

Moderate-to-Severe Mitral Stenosis:

Warfarin is required for moderate-to-severe mitral stenosis—DOACs are contraindicated. 1, 2

---

When Warfarin is PREFERRED Over DOACs (Relative Indications)

Severe Renal Dysfunction:

For CrCl <15 mL/min or patients on hemodialysis, warfarin is preferred (INR 2.0-3.0). 1, 2

• DOACs lack clinical trial evidence in end-stage renal disease 1
• Dabigatran and rivaroxaban specifically not recommended in dialysis patients 1

Left Ventricular Thrombus:

Warfarin with target INR 2.0-3.0 is preferred for documented left ventricular thrombus. 2

Significant Drug-Drug Interactions:

When patients require strong CYP3A4/P-glycoprotein inhibitors or inducers that preclude DOAC use, warfarin is the alternative. 2, 3

Cost/Access Barriers:

When DOACs are not accessible due to formulary restrictions or cost, warfarin remains appropriate if TTR can be maintained ≥70%. 1

---

When DOACs are PREFERRED Over Warfarin

For all eligible patients with nonvalvular atrial fibrillation, DOACs are strongly recommended over warfarin. 1

Specific Clinical Scenarios Favoring DOACs:

Poor INR Control:

Switch from warfarin to DOAC when TTR consistently <65% despite interventions. 1

• Implement SAMe-TT2R2 score: scores >2 predict poor TTR and favor DOAC initiation 1

High Bleeding Risk:

For patients with prior unprovoked bleeding, warfarin-associated bleeding, or high bleeding risk, prefer apixaban, edoxaban, or dabigatran 110 mg (where available). 1

• All three demonstrate significantly less major bleeding than warfarin 1

Prior Gastrointestinal Bleeding:

Apixaban or dabigatran 110 mg are preferable—they are the only DOACs without increased GI bleeding risk versus warfarin. 1

High Ischemic Stroke Risk:

Dabigatran 150 mg twice daily is the only agent with superior efficacy versus warfarin for stroke prevention. 1

• Must balance against bleeding risk assessment 1

Risk of Intracranial Hemorrhage:

All DOACs demonstrate significantly fewer intracranial hemorrhages than warfarin. 4

• Dabigatran: 72% reduction (HR 0.28) 4
• Rivaroxaban: 60% reduction (HR 0.40) 4
• Apixaban: 44% reduction (HR 0.56) 4

---

Monitoring Requirements

Warfarin:

• Weekly INR monitoring during initiation 1
• Monthly INR monitoring when stable 1
• Within one week before high-risk procedures 2

DOACs:

• No routine laboratory monitoring required 2
• Renal function monitoring essential (dabigatran particularly sensitive to renal impairment) 3

---

Common Pitfalls to Avoid

Lower INR Targets in Asian Populations:

Despite practice in some Asian countries using INR 1.6-2.6, moderate-quality evidence shows lower INR targets (approximately 1.5-2.0) increase thromboembolism by 50% (RR 1.50) while reducing bleeding by 46% (RR 0.54). 5

• Standard INR 2.0-3.0 should remain the target until higher-quality data demonstrate otherwise 5

Underdosing DOACs:

Use full standard DOAC doses unless specific dose-reduction criteria are met to prevent avoidable thromboembolic events. 6

• Dabigatran dose reduction to 110 mg twice daily only for: age ≥80 years, concomitant verapamil, age 75-80 with moderate renal impairment, gastritis/GERD, or increased bleeding risk 6

Bridging Therapy Misconceptions:

For patients with AF without mechanical valves undergoing procedures, bridging decisions must balance stroke versus bleeding risk—not all patients require bridging. 1

• Mechanical valve patients require bridging with UFH or LMWH 1